We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioVendor Acquires All Shares of DIAsource ImmunoAssays SA

By LabMedica International staff writers
Posted on 16 Oct 2017
BioVendor - Laboratornímedicínaa.s. (Brno, Czech Republic), an international diagnostics holding, has acquired 100% of the shares of DIAsourceImmunoAssays SA (Louvain-La-Neuve, Belgium) from Anteo Diagnostics (Queensland, Australia), which had acquired DIAsource in January 2016.

DIAsource specializes in the development, in manufacturing, sales and distribution of immunoassay tests and open instrumentation solutions for clinical medical diagnostics. The company is a leading provider in IVD market segments such as Vitamin D, ELISA and RIA assays, with its clinical diagnostics product catalog featuring over 190 ELISA and 140 RIA assays.

The acquisition of DIAsource has extended BioVendor’s broad panel of ELISA and RIA assays, antibodies and reagents for clinical diagnostics, as well as established a direct sales presence in Belgium, France and Spain, and a worldwide network of over 100 sales and distribution partners in over 70 countries. DIAsource represents BioVendor’s largest acquisition to date and follows previous acquisitions carried out since 2014 in line with its long-term plan of international expansion.


New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Rocking Shaker
HumaRock
New
Urine Strips
11 Parameter Urine Strips

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests